10x Genomics Wins Patent Verdict Against Parse Biosciences, but Core Growth Challenges Persist

What happened

10x Genomics secured a jury verdict finding Parse Biosciences infringed its patents, marking another IP victory for the company's single-cell technology portfolio. The verdict likely entitles 10x to damages or royalties, adding to a string of legal wins that have previously generated settlement income. However, this development does little to address the company's core operational problems: instrument sales have declined over 35% year-over-year in recent quarters, total products and services revenue is flat-to-down, and growth relies heavily on spatial consumables and non-recurring IP licensing. While the ruling may deter further competitive encroachment and provide near-term cash, the fundamental issue of stagnant organic demand in a constrained academic funding environment remains unresolved. Investors should distinguish between headline legal wins and the underlying business trajectory, which the DeepValue report identifies as a potential sell.

Implication

For investors, the verdict reinforces 10x Genomics' intellectual property moat and may yield additional royalty income, but it should not be viewed as a game-changer. The company has already collected significant non-recurring IP settlements that inflated 2025 results, and management has explicitly labeled these as non-recurring, meaning the market should not capitalize them as permanent earnings. The key metrics to watch remain instrument placements and consumables growth, particularly in spatial biology, which have not yet shown a convincing recovery. Over the next 12-18 months, the potential integration of Scale Biosciences and the outcome of NIH funding policy will have a far greater impact on the stock than any single litigation win. We maintain our cautious stance and would use any price spike from this news as an opportunity to reduce exposure given the unfavorable risk-reward at current valuations.

Thesis delta

The verdict does not alter our overall rating of POTENTIAL SELL. It reinforces the strength of TXG's IP portfolio and could provide incremental royalty payments, but this does not offset the fundamental headwinds of declining instrument revenue, flat core product sales, and heavy reliance on non-recurring IP income. We maintain that the stock is overvalued relative to its organic growth prospects.